Key result
Adding mexiletine and amiodarone metabolite levels improves neural network predictions of post-treatment QTc and QRS.
Why the study?
Do plasma concentrations of mexiletine, amiodarone, and their active metabolites predict changes in QRS and QTc intervals in patients treated for ventricular arrhythmias?
Observational (n=71)
Do plasma concentrations of mexiletine, amiodarone, and their active metabolites predict changes in QRS and QTc intervals in patients treated for ventricular arrhythmias?
Answers are grounded in this paper and cite their sources.
The synergistic improvement in predicting QRS and QTc changes using both mexiletine and amiodarone metabolite concentrations suggests a nonlinear therapeutic interaction between the two drugs.
Introduction: Amiodarone (Amio) is a first-line medical therapy for ventricular arrhythmia. If patients do not respond to Amio or experience significant side-effects, mexiletine (Mex), a class Ib anti-arrhythmic agent, is often prescribed in addition to or in lieu of Amio. Both drugs undergo extensive metabolism, resulting in several active metabolites. The nonlinear effects of Amio and Mex interaction on the action potential significantly impacts whether the combined therapy is effective in treating patients with refractory ventricular arrhythmias. Hypothesis: The plasma concentrations of Mex, Amio, and their active metabolites influence changes in QRS and QTc, markers for ventricular arrhythmia risk. Methods: Patients recently or chronically prescribed Mex, including those concurrently receiving Amio, were enrolled. Plasma drug and metabolite concentrations were determined. Pre- and post-Mex ECG parameters were collected. Neural network models were constructed to predict post-Mex QRS and QTc using combinations of pre-Mex QRS and QTc, as well as drug and metabolite concentrations, as input variables. Results: 71 patients were enrolled in the study. 18 patients started Mex within 48 hours of enrollment, 53 were prescribed Mex for > 1 month prior, and 51 were also prescribed Amio. Plasma concentrations varied (median [range] in microgram/L): Mex 603 [0-2000], hydroxymethyl-Mex 65 [0-363], m-hydroxy-Mex 44 [0-358], Amio 1105 [0-22100], N-monodesethyl-Amio 920 [0-2060], and N,N-didesethyl-Amio 57 [0-129]. Baseline models using pre-Mex QTc and QRS values modestly predicted post-Mex QTc (R 2 = 0.26) and QRS (R 2 = 0.16). However, adding Amio and its metabolite concentrations enhanced the predictions (R 2 = 0.27 for QTc, 0.22 for QRS). Similarly, including Mex and its metabolite concentrations improved the predictions (R 2 = 0.28 for QTc, 0.20 for QRS). Notably, adding both Mex, Amio, and their metabolites synergistically boosted the predictions (R 2 = 0.32 for QTc, 0.28 for QRS). Conclusion: Synergistic improvement in model to predict changes in QRS and QTc when using Mex, Amio, and their metabolite concentration implies nonlinear therapeutic interaction, showing that the combined therapy is not additive. Future work should investigate the therapeutic implications of this interaction.
No takes yet. Share an insight, caveat, or question.
Dang et al. (2025) conducted an observational in Ventricular arrhythmia (n=71). Mexiletine and Amiodarone plasma concentrations vs. Baseline pre-Mex QTc and QRS values was evaluated on Post-Mex QRS and QTc. Adding plasma concentrations of mexiletine, amiodarone, and their metabolites synergistically improved neural network predictions of post-mexiletine QTc and QRS.
Synapse has enriched 10 related papers. Consider them for comparative context: